Allogeneic stem cell therapy - Athersys

Drug Profile

Allogeneic stem cell therapy - Athersys

Alternative Names: AMI MultiStem; HLCM051; MultiStem; PF-05285401; PF-5285401

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Athersys
  • Developer Athersys; Case Western Reserve University; MiSOT; University of Texas Health Science Center at Houston
  • Class Antiparkinsonians; Cardiovascular therapies; Heart failure therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I; Graft-versus-host disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Graft-versus-host disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Myocardial infarction; Respiratory distress syndrome; Stroke
  • Phase I Graft-versus-host disease; Transplant rejection
  • Preclinical Brain injuries; Diabetes mellitus; Heart failure; Mucopolysaccharidosis I; Multiple sclerosis; Parkinson's disease; Peripheral vascular disorders; Spinal cord injuries
  • Discontinued Ulcerative colitis

Most Recent Events

  • 20 Mar 2017 Athersys plans the phase III MASTERS-2 trial in Stroke in US, Canada, Europe
  • 09 Mar 2017 Allogenic stem cell therapy receives priority review status for Stroke in Japan
  • 28 Sep 2016 Atherys receives Special Protocol Assessment designation from the US FDA regarding the registration study design for phase III trial in Stroke in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top